Prothena Corporation plc
0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS
Case Summary | |
Company Name: | Prothena Corporation plc |
Stock Symbol : | NASDAQ: PRTA |
Class Period Start: | 10/15/2015 |
Class Period End: | 04/20/2018 |
Lead Plaintiff motion: | 07/16/2018 |
Date Filed: | 05/15/2018 |
Type of Case: | Securities Class Action |
Court: | U.S. District Court for the Northern District of California |
Summary: | Thieler Law Corp advises investors with losses exceeding $100,000 of the July 16, 2018 lead plaintiff deadline in a class action lawsuit filed against Prothena Corporation plc (NASDAQ: PRTA) (“Prothena” or “the Company”). The suit is pending in the U.S. District Court for the Northern District of California and investors, who purchased Prothena Corporation plc securities between October 15, 2015 and April 20, 2018, have until July 16, 2018 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class. If you purchased Prothena Corporation plc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class. The complaint alleges that during the Class Period, Prothena violated the Exchange Act by misleading investors regarding its development of NEOD001, an antibody designed to treat AL amyloidosis, a debilitating disease that can lead to organ failure and death. Throughout the Class Period, defendants misleadingly cited the results of Prothena's ongoing Phase 1/2 clinical study of NEOD001 as evidence that the drug was effective and provided a strong basis for late-stage Phase 2b and Phase 3 studies of NEOD001. In truth, NEOD001 was not an effective treatment for AL amyloidosis and did not provide an adequate basis for the late-stage Phase 2b and Phase 3 studies. On October 15, 2015, the Company revealed its late-stage Phase 2b “PRONTO” study and expansion of its Phase 1/2 clinical trial for the antibody NEOD001. On April 23, 2018, the Company revealed it was ending development of NEOD001 after its Phase 2b PRONTO trial failed to reach either its primary or secondary endpoints. Following this news, NASDAQ: PRTA fell $25.34, or nearly 69%, to close at $11.50 on April 23, 2018. If you were negatively impacted by your investment in Prothena Corporation plc securities between October 15, 2015 and April 20, 2018 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation. Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Thieler Law Corp 2534 State Street - Suite 406, San Diego, CA 92101 by email: mail@thielerlaw.com or telephone at +1 (619) 377 - 4324 or visit our website http://www.thielerlaw.com/ or Facsimile: +1 (619) 785 – 3185 |